Summary
Since Bromocriptine is used to restore fertility in hyperprolactinemic women, its safety in pregnancy and the offspring was investigated in a stepwise approach: (i) the first survey in pregnancy was based on spontaneous reporting, (ii) the second investigation was conducted at 33 clinics as an intensive monitoring project and, (iii) the third study consisted in a full examination of children up to the age of 9 years who had been exposed to Bromocriptine in utero. The data collated in this program includes information on 2587 pregnancies in 2437 women treated with Bromocriptine during some stage of gestation, and follow-up examinations for 988 infants. The results show that the use of Bromocriptine in the treatment of infertility in women is not associated with an increased risk of spontaneous abortion, multiple pregnancy or the occurrence of congenital malformation in their progeny. Moreover, exposure to this drug in utero has no adverse influence on the postnatal development.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anonymous National Foundation/March of Dimes (1975) Facts. National Foundation, New York
del Pozo E, Krupp P (1984) Endocrine effects of dopamine receptor stimulation on the fetal-maternal unit. Drugs and Pregnancy. Academic Press, London, pp 191–201
Deutsche Forschungsgemeinschaft (German Research Council) (1977) Schwangerschaftsverlauf und Kindsentwicklung. Harald Boldt, Boppard, S 86
Franks S, Jacobs HS, Hull MG (1977) Management of hyperprolactinaemic amenorrhoea. Br J Obstet Gynaecol 84:241
Heinonen OP, Slone D, Shapiro S (1977) Birth defects and drugs in pregnancy. Publishing Sciences Group, Littleton, Ill
Helbing W (1966) Pathologie der Frühschwangerschaft. In: Döderlein G, Wulf KH (Hrsg) Klinik der Frauenheilkunde und Geburtshilfe 5. Urban und Schwarzenberg, München, S 22
Kurachi K, Aono T, Koike K et al. (1983) A follow-up of infants born to mothers treated with bromocriptine. Obstet Gynecol (Tokyo) 50:126–131
Raymond JP, Goldstein E, Konopka P et al. (1985) Follow-up of children born of bromocriptine-treated mothers. Horm Res 22:239–246
Richardson BP, Turkalj I, Flückiger E (1984) Bromocriptine. In: Lawrence DR (ed) Safety and testing of new drugs, prediction and performance. Academic Press, London, pp 19–63
Schellekens LA, Snuiverink H, van den Berghe H (1977) Chromosomal pattern of children born after induction of ovulation with bromocriptine. Drug Res 27:2151
Sholtz R, Goldstein H, Wallace HM (1976) Incidence and impact of fetal and perinatal disease. In: Brent RL, Harris MI (eds) Prevention of embryonic, fetal and perinatal disease. US Government Printing Office, Washington, DC, pp 1–18
The Study Group of Hyperprolactinemia (1985) Survey of infants born to mothers treated with Bromocriptine. 8th Study Group Meeting, Osaka
Thorner MO, Besser GM, Jones A (1975) Bromocriptine treatment of female infertility: Report of 13 pregnancies. Br Med J IV:964
Turkalj I, Braun P, Krupp P (1982) Surveillance of bromocriptine in pregnancy. J Am Med Assoc 247:1589
Weil C (1986) The safety of bromocriptine in hyperprolactinaemic female infertility: A literature review. Curr Med Res Opin 10:172
Author information
Authors and Affiliations
Additional information
The active ingredient of Parlodel®
Rights and permissions
About this article
Cite this article
Krupp, P., Monka, C. Bromocriptine in pregnancy: Safety aspects. Klin Wochenschr 65, 823–827 (1987). https://doi.org/10.1007/BF01727477
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01727477